Literature DB >> 25626682

Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation.

Mohamed El-Far1,2, Petronela Ancuta1,2, Jean-Pierre Routy3, Yuwei Zhang4,1,2, Wendy Bakeman4, Rebeka Bordi4,2, Sandrina DaFonseca4,1,2, Elias A Said1,2, Annie Gosselin2, Tévy-Suzy Tep1,2, Quentin Eichbaum5, Julien van Grevenynghe4,1,2, Olivier Schwartz6, Gordon J Freeman7, Elias K Haddad4,2, Nicolas Chomont4,1,2, Rafick-Pierre Sékaly2,8,1,4.   

Abstract

CTLA-4 is a negative regulator of T-cell receptor-mediated CD4(+) T-cell activation and function. Upregulation of CTLA-4 during human immunodeficiency virus type 1 (HIV-1) infection on activated T cells, particularly on HIV-specific CD4(+) T cells, correlates with immune dysfunction and disease progression. As HIV-1 infects and replicates in activated CD4(+) T cells, we investigated mechanisms by which HIV-1 modulates CTLA-4 expression to establish productive viral infection in these cells. Here, we demonstrate that HIV-1 infection in activated CD4(+) T cells was followed by Nef-mediated downregulation of CTLA-4. This was associated with a decreased T-cell activation threshold and significant resistance to CTLA-4 triggering. In line with these in vitro results, quantification of pro-viral HIV DNA from treatment-naive HIV-infected subjects demonstrated a preferential infection of memory CD4(+)CTLA-4(+) T cells, thus identifying CTLA-4 as a biomarker for HIV-infected cells in vivo. As transcriptionally active HIV-1 and Nef expression in vivo were previously shown to take place mainly in the CD3(+)CD4(-)CD8(-) [double-negative (DN)] cells, we further quantified HIV DNA in the CTLA-4(+) and CTLA-4(-) subpopulations of these cells. Our results showed that DN T cells lacking CTLA-4 expression were enriched in HIV DNA compared with DN CTLA-4(+) cells. Together, these results suggested that HIV-1 preferential infection of CD4(+)CTLA-4(+) T cells in vivo was followed by Nef-mediated concomitant downregulation of both CD4 and CTLA-4 upon transition to productive infection. This also highlights the propensity of HIV-1 to evade restriction of the key negative immune regulator CTLA-4 on cell activation and viral replication, and therefore contributes to the overall HIV-1 pathogenesis.
© 2015 The Authors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25626682      PMCID: PMC4635491          DOI: 10.1099/vir.0.000065

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  CTLA-4+PD-1- Memory CD4+ T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques.

Authors:  Colleen S McGary; Claire Deleage; Justin Harper; Luca Micci; Susan P Ribeiro; Sara Paganini; Leticia Kuri-Cervantes; Clarisse Benne; Emily S Ryan; Robert Balderas; Sherrie Jean; Kirk Easley; Vincent Marconi; Guido Silvestri; Jacob D Estes; Rafick-Pierre Sekaly; Mirko Paiardini
Journal:  Immunity       Date:  2017-10-17       Impact factor: 31.745

2.  Kinetics of HIV-1 Latency Reversal Quantified on the Single-Cell Level Using a Novel Flow-Based Technique.

Authors:  G Martrus; A Niehrs; R Cornelis; A Rechtien; W García-Beltran; M Lütgehetmann; C Hoffmann; M Altfeld
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

Review 3.  Immune checkpoint blockade in infectious diseases.

Authors:  Michelle N Wykes; Sharon R Lewin
Journal:  Nat Rev Immunol       Date:  2017-10-09       Impact factor: 53.106

4.  The HIV-1 accessory proteins Nef and Vpu downregulate total and cell surface CD28 in CD4+ T cells.

Authors:  Emily N Pawlak; Brennan S Dirk; Rajesh Abraham Jacob; Aaron L Johnson; Jimmy D Dikeakos
Journal:  Retrovirology       Date:  2018-01-12       Impact factor: 4.602

Review 5.  Immune Checkpoint Inhibitors in Melanoma and HIV Infection.

Authors:  Antonio Marra; Giosuè Scognamiglio; Ilaria Peluso; Gerardo Botti; Celeste Fusciello; Amelia Filippelli; Paolo A Ascierto; Stefano Pepe; Francesco Sabbatino
Journal:  Open AIDS J       Date:  2017-11-14

Review 6.  The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV Cure?

Authors:  Hui Chen; Maha Moussa; Marta Catalfamo
Journal:  Front Immunol       Date:  2020-07-02       Impact factor: 7.561

Review 7.  Immune checkpoint blockade in HIV.

Authors:  Celine Gubser; Chris Chiu; Sharon R Lewin; Thomas A Rasmussen
Journal:  EBioMedicine       Date:  2022-02-02       Impact factor: 8.143

8.  Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapy.

Authors:  Justin Harper; Susan P Ribeiro; Chi Ngai Chan; Malika Aid; Claire Deleage; Luca Micci; Maria Pino; Barbara Cervasi; Gopalan Raghunathan; Eric Rimmer; Gulesi Ayanoglu; Guoxin Wu; Neeta Shenvi; Richard Jo Barnard; Gregory Q Del Prete; Kathleen Busman-Sahay; Guido Silvestri; Deanna A Kulpa; Steven E Bosinger; Kirk A Easley; Bonnie J Howell; Dan Gorman; Daria J Hazuda; Jacob D Estes; Rafick-Pierre Sekaly; Mirko Paiardini
Journal:  J Clin Invest       Date:  2022-04-15       Impact factor: 19.456

Review 9.  Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection.

Authors:  Yuting Sun; Jing Xue
Journal:  Viruses       Date:  2022-03-11       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.